Treatment (T) of metastatic colorectal cancer (mCRC) patients (pts) ≥75 years (y) old in clinical practice: A multicenter analysis

被引：1
|
作者：
Grande, Roberta
Garufi, Carlo
Pavese, Ida
Ciancola, Fabrizio
Gamma, Donatello
Pellegrino, Arianna
Di Lauro, Luigi
Corsi, Domenico C.
Signorelli, Diego
Sperduti, Isabella
Cortese, Giada
Risi, Emanuela
Moreno, Federica
Sergi, Domenico
Signorelli, Carlo
Natoli, Clara
Ruggeri, Enzo
Zampa, Germano
Russano, Marco
Gamucci, Teresa
机构：
[1] ASL Frosinone, Med Oncol Unit, Frosinone, Italy
[2] Regina Elena Inst Canc Res, Rome, Italy
[3] UOC Oncol Osped San Pietro Fatebenefratelli, Rome, Italy
[4] Policlin Umberto 1, Rome, Italy
[5] Osped San Giovanni Calibita, Fatebenefratelli Isola Tiberina, Rome, Italy
[6] Ist Nazl Tumori Regina Elena, Rome, Italy
[7] Univ G DAnnunzio, Chieti, Italy
[8] Univ Roma La Sapienza, Div Med Oncol, I-00185 Rome, Italy
[9] ASL Viterbo, Div Med Oncol, Viterbo, Italy
[10] Belcolle Hosp, Med Oncol Unit, Viterbo, Italy
[11] UOSA Oncol ASL RM A, Rome, Italy
[12] Campus Biomed Univ, Dept Med Oncol, Rome, Italy
[13] ASL Frosinone, Med Oncol Unit, Sora, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e14514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14514
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Aflibercept (Afl) for patients (pts) with metastatic colorectal cancer (mCRC): Clinical predictors of nonhematologic (nonhem) toxicity.
    Vladimirova, Liubov Yu
    Fedyanin, Mikhail
    Chubenko, Viacheslav
    Fakhrudinova, Olga
    Bolotina, Larisa
    Moiseenko, Fedor Vladimirovich
    Khasanova, Alfiya
    Belonogov, Alexandr
    Musaeva, Hedi
    Novikova, Olga
    Stradaeva, Irina
    Mukhametshina, Guzel
    Orlova, Rashida
    Feoktistova, Polina
    Kuzmina, Evgeniya
    Karabina, Elena
    Nekrasova, Oksana
    Sherstnev, Viktor
    Micshenko, Andrey
    Tjulandin, Sergei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] Prognostic factors of patients (pts) with salvage-line metastatic colorectal cancer (mCRC)
    Bando, Hideaki
    Oki, Eiji
    Takeda, Yuriko
    Misumi, Toshihiro
    Suzuki, Motoko
    Wakabayashi, Masashi
    Yamazaki, Kentaro
    Grothey, Axel
    Mayer, Robert J.
    Li, Jin
    Andre, Thierry
    Shi, Qian
    De Gramont, Aimery
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 115 - 115
  • [23] EFFICACY AND SAFETY OF CAPECITABINE AND IRINOTECAN (CAPIRI) IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Bounedjar, Adda
    Smaili, Farida
    ANNALS OF ONCOLOGY, 2011, 22 : v99 - v99
  • [24] Prognostic significance of KRAS mutation rate in metastatic colorectal cancer (mCRC) patients (pts).
    Vincenzi, Bruno
    Loupakis, Fotios
    Bianchi, Andrea Sartore
    Russo, Antonio
    Mannavola, Francesco
    Perrone, Giuseppe
    Cremolini, Chiara
    Rossini, Daniele
    Ongaro, Elena
    Bonazzina, Erica
    Dell'Aquila, Emanuela
    Imperatori, Marco
    De Maglio, Giovanna
    Falcone, Alfredo
    Santini, Daniele
    Onetti-Muda, Andrea
    Siena, Salvatore
    Aprile, Giuseppe
    Tonini, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Prognostic effect of RAS/BRAF mutations in patients (pts) with metastatic colorectal cancer (mCRC)
    Abid, Haisam
    Szabo, Aniko
    Taylor, Bradley W.
    Shreenivas, Aditya V.
    Chakrabarti, Sakti
    Kamgar, Mandana
    Thomas, James P.
    George, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [26] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (Pts) with metastatic colorectal cancer (MCRC)
    Laudani, A.
    Savio, G.
    Leonardi, V.
    Palmisano, V.
    Tartaglia, L.
    Manuguerra, G.
    Pepe, A.
    Alu, M.
    Usset, A.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
  • [27] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (PTS) with metastatic colorectal cancer (MCRC)
    Laudani, Agata
    Savio, Giuseppina
    Leonardi, Vita
    Palmisano, Valentina
    Rondello, Giacomo
    Alu, Massimiliano
    Pepe, Alessio
    Calabria, Caterina
    Usset, Antonella
    Agostara, Biagio
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [28] Analysis of clinical characteristics and survival trends of patients with metastatic colorectal cancer (mCRC) receiving ≥3 lines of treatment
    Bringas Beranek, M.
    Gutierrez Alonso, N.
    Soto Alsar, J.
    A. Gutierrez Ortiz De la Tabla
    Lopez Jimenez, C.
    Alva Bianchi, M.
    Jimenez Rodriguez, R.
    Martin Lozano, R.
    Ortega Moran, L.
    Torres Perez-Solero, G.
    Munoz Martin, A.
    Calvo, A.
    Blanco, M.
    Arregui Valles, M.
    Aparicio Salcedo, M. I.
    Martin, M.
    Garcia-Alfonso, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S578 - S578
  • [29] TAS-102 versus placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial.
    Van Cutsem, Eric
    Benedetti, Fabio M.
    Mizuguchi, Hirokazu
    Mayer, Robert J.
    Falcone, Alfredo
    Garcia-Carbonero, Rocio
    Tabernero, Josep
    Sobrero, Alberto F.
    Peeters, Marc
    Zaniboni, Alberto
    Yoshino, Takayuki
    Shimada, Yasuhiro
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Hochster, Howard S.
    Lenz, Heinz-Josef
    Ben Tran
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [30] Weekly low dose irinotecan and daily oral anticancer drug chemotherapy for metastatic colorectal cancer (MCRC) patients more than 75 years old
    Sasaki, K.
    Takasaka, H.
    Sawada, T.
    Ezoe, E.
    Araya, J.
    Takada, Y.
    Furuhata, T.
    Hirata, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345